





Present

YEAR IN REVIEW BREAST CANCER

The year that was...2016

21st - 22nd January 2017, Mumbai

WHAT IF THERE WAS SOMEONE WHO WANTED YOU TO EXCEL BEFORE IT'S TOO LATE

Someone who respects your time. Someone you could trust to get opinion. Someone who judged survival by whether they helped you succeed. That someone is "team year in review", your scientific advisors. And they're back to work for you.

Participants will get 4 CME points

SAVE THE DATE

Year in Review Breast & Gynec Cancers Conference, 19th - 21st Jan 2018 R. D. Choksi Auditorium, Tata Memorial Hospital, Mumbai Dear Colleagues,

Women's Cancer Initiative - Tata Memorial Hospital and Nag Foundation are delighted to invite you for the "2nd Year in Review: Breast Cancer Conference" to be held on Sat 21st - Sun 22nd Jan 2017 at R. D. Choksi Auditorium, Tata Memorial Hospital, Parel, Mumbai.

Our idea is to recapitulate the best breast cancer science every year in a "Year in Review" format. The theme of this meeting is "Breast Cancer...the year that was 2016". We strive to recapitulate the best original science presented at the major conferences of the immediately preceding year.

From these major conferences, we intend to cover surgical, radiation, medical, pathology, biomarkers and imaging issues making this meeting a truly multi-disciplinary one.

We believe that presentation of the most impactful and important abstracts/full text publications from all important conferences in the preceding year will give the participants a feel of the landscape of breast cancer research, especially that impacts practice. At the end of every session there will be rapid review presentation on additional abstracts. The selection of abstracts/full text publications is based on originality, innovation and potential impact on clinical practice.

The meeting proceedings of the "1st Year in Review Conference" and many more meetings are fully archived on www.yearinreview.in

We hope to benefit from your presence and wisdom in nurturing this idea.

Regards,

Conference Chairpersons Dr. Sudeep Gupta Dr. Shona Nag



International Faculty

Dr. Hope S Rugo, USA

Dr. Bhawna Sirohi, UK

Dr. Shaheenah Dawood, Dubai

Scientific Committee

Dr. Amit Agarwal

Dr. Amit Verma

Dr. Anusheel Munshi

Dr. Bhawna Sirohi

Dr. Chirag Desai

Dr. Govind Babu

Dr. G S Bhattacharyya

Dr. Hemant Malhotra

Dr. Hope Rugo

Dr. Nishitha Shetty

Dr. Nita Nair

Dr. Shaheenah Dawood

Dr. Shalaka Joshi

Dr. Sanjoy Chatterjee

Dr. Senthil Rajappa

Dr. Randeep Singh

Dr. T Raja

Dr. Vineet Gupta

2016 Conferences Reviewed

AACR Annual Meeting 2016

(American Association for Cancer Research)

ASCO Annual Meeting 2016

(American Society of Clinical Oncology)

10th EBCC 2016

(European Breast Cancer Conference)

ESMO Congress 2016

(European Society for Medical Oncology)

ASTRO Annual Meeting 2016

(American Society for Radiation Oncology)

ESTRO Annual Meeting 2016

(European Society for Radiotherapy & Oncology)

SABCS 2016

(San Antonio Breast Cancer Symposium)

ASBC 2016

(Annual conference of American Society of Breast surgery)

SSO 2016

(Annual conference of Society of Surgical Oncology)

MASCC 2016

(MASCC/ISOO Annual Meeting on Supportive Care in Cancer)



Season's Greetings From all of us at team YIR



Journals Reviewed

- New England of Journal of Medicine
- Journal of Clinical Oncology
- Annals of Oncology
- Annals of Surgery
- Journal of National Cancer Institute
- JAMA Oncology
- The Lancet
- Lancet Oncology
- Nature
- Nature Genetics
- British Journal of Cancer
- European Journal of Cancer
- The Oncologist
- International Journal of Radiation Oncology, Biology & Physics
- Clinical Cancer Research
- Journal of Experimental & Clinical Cancer Research
- JAMA Cardiology
- PLOS Genetics
- Breast Cancer Research
- Bio Medical Central

-And many more

Websites Reviewed

- Practice Update
- ASCOPOST
- ASCO Reading Room
- · Clinical Cancer Options
- Prime Oncology
- Medscape
- Oncolive

-And many more

Session Classifications

- · Loco-regional Issues
- ER positive
- HER2 positive
- Triple negative
- Translational Science
- Supportive Care
- State-of-the-Science Presentations
- Rapid Reviews





Highlights of the Meeting

03 Keynote talk on extended adjuvant 02 endocrine therapy in breast cancer Major International conferences journals & websites More than 100 reviewed abstracts to be discussed Comprehensive update on Practice breast cancer impacting panel discussions & debates



About International Faculty



Dr. Hope Rugo, USAClinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, UCSF San Francisco, CA

Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and a is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.





About International Faculty



Dr. Shaheenah Dawood, Dubai

Dr. Shaheenah Dawood is the Head of Medical Oncology and the Head of the Breast Cancer Program at Dubai Hospital in the United Arab Emirates. Dr. Dawoodcompleted her M.B.B.Ch at Dubai Medical College in 1998 and a Master of Public Health degree at the Harvard School of Public Health, Boston, USA in 2008. Her postgraduate medical training programs include a Fellowship at McGill University in Canada in 2006, and the Susan Komen Breast Cancer Fellowship at the University of Texas M.D. Anderson Cancer Center in 2007.

Dr. Dawood is a member of various professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the Canadian Association of Medical Oncologists, the Emirates Medical Association, and the Inflammatory Breast Cancer Research Group. She is also the co-director of the Middle East Research Network.

Dr. Dawood has been a primary author or collaborator on over 50 peer-reviewed publications in national and international journals. In addition, she has collaborated with other authors to write a number of book chapters. Dr. Dawood has also been involved as a journal reviewer and as an editorial consultant for many cancer-related journals.

Research Interests:

Dr. Dawood's researcher interests encompass Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastases, as well as life-style issues and survival outcome of cancer patients.



National Faculty

Dr. A K Malhotra

Dr. A K Vaid

Dr. Adwaita Gore

Dr. Amish Dalal

Dr. Amit Agarwal

Dr. Amit Dutt

Dr. Amit Verma

Dr. Amol Dongre

Dr. Anil Heroor

Dr. Anita Ramesh

Dr. Anubha Bharthuar

Dr. Anupama Mane

Dr. Anusheel Munshi

Dr. Archana Shetty

Dr. Arun Warrior

Dr. Asha Kapadia

Dr. Ashish Bakshi

Dr. Ashish Kaushal

Dr. Ashish Singh

Dr. Ashwini Budrukkar

Dr. Avinash Deo

Dr. AVS Suresh

Dr. B K Smruti

Dr. Bharat Bhosale

Dr. Bharat Parikh

Dr. Bhavna Parikh

Dr. Boman Dhabhar

Dr. C B Koppiker

Dr. C J Tamane

Dr. Chanchal Goswami

Dr. Chetan Deshmukh

Dr. Chirag Desai

Dr. D C Doval

Dr. Devavrat Arva

Dr. Dinesh Pendharkar

Dr. G S Bhattacharyya

Dr. G S Chowdhary

Dr. Gaurav Agarwal

Dr. Gaurav Gupta

Dr. Gurpreet Singh

Dr. Hemant Malhotra

Dr. Indumati Ambulkar

Dr. J K Singh

Dr. J S Sekhon

Dr. Java Ghosh

Dr. Jeremy Pautu

Dr. Jyoti Bajpai

Dr. K Pavithran

Dr. K C Gopinath

Dr. K.C.Lakshmajah

Dr. Kaial Shah

Dr. Kannan Kalaichelvi

Dr. Kaustav Talapatra

Dr. Kishore Kumar

Dr. Krishna Prasad

Dr. Madhuchanda Kar

Dr. Manish Chandra

Dr. Manish Kumar

Dr. Manish Singhal

Dr. Manisha Singh

Dr. Mehboob Basade

Dr. Muzammil Shaikh

Dr. N Sudhakar

Dr. N K Warrier

Dr. Namita Pandey

Dr. Nikhil Ghadvalpatil

Dr. Nirmal Raut

Dr. Nita Nair

Dr. Nitesh Rohatgi

Dr. P P Bapsy

Dr. Poonam Patil

Dr. Prasad Dandekar

Dr. R K Deshpande

Dr. Raiesh Vashistha

Dr. Raiiv Sarin

Dr. Ramesh Bilimagga

Dr. Ramesh Nimmagadda

Dr. Ramesh Sarin

Dr. Ranga Rao

Dr. Reetu Jain

Dr. Reiiv Raiendranath

Dr. S D Banavali

Dr. S.H. Advani

Dr. Sadashivadu Gundeti

Dr. Sandeep Govle

Dr. Sanjay Sharma

Dr. Sanjoy Chatterjee

Dr. Sankar Srinivasan

Dr. Santam Chakraborty

Dr. Seema Gulia

Dr. Selvi Radhakrishna

Dr. Senthil Rajappa

Dr. Shailesh Bondarde

Dr. Shailesh Talati

Dr. Shalaka Joshi

Dr. Shekhar Patil

Dr. Shekhar Salkar

Dr. Shirish Alurkar

Dr. Shona Nag

Dr. Shyam Aggarwal

Dr. Somashekar S P

Dr. Srinivas Chakravarthy

Dr. Sudeep Gupta

Dr. SVSS Prasad

Dr. T P Sahoo

Dr. T Raia

Dr. Tabassum W.

Dr. Tanuia Shet

Dr. Tanweer Shahid

Dr. Tomcha Singh

Dr. V Kannan

Dr. Vashishth Maniar

Dr. Vedant Kabra

Dr. Vijay Agarwal

Dr. Vijav Haribhakti

Dr. Vijaykumar DK

Dr. Vikram Maiya

Dr. Vinod Raina





Day 1 - Saturday, 21st January 2017

08.30-09.00 (30mins)



Registration

09.00-11.00 Session 1: Locoregional Therapies in Breast Cancer

Chairpersons: C B Koppiker, Gaurav Agarwal

09.00-09.15 (15mins)

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial

Author: Giuliano AF Reference: Ann Surg. 2016 Sep; 264(3):413-20

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): follow-up of a prospective multi-institutional cohort

Author: Jean-Marc Classe Conference: 2016 SABCS S2-07

国 Improved axillary evaluation following neoadjuvant therapy for patients with node positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection

Author: Abigail Caudle Reference: J Clin Oncol. 2016 Apr 1;34(10):1072-8



Reviewer: Ramesh Sarin

09.15-09.30 (15mins)

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

Author: Monica Morrow Reference: J Clin Oncol 34:4040-4046

Ball Neoadjuvant Endocrine Therapy for Estrogen Receptor - Positive Breast Cancer - A Systematic Review and Meta-analysis

Author: Laura M. Spring Reference: JAMA Oncol. 2016 Nov 1;2(11):1477-1486



Reviewer: Selvi Radhakrishna



Day 1 - Saturday, 21st January 2017

09.30-09.45 (15mins)

After 10 Years, Postmastectomy Radiation Is Shown to Improve Local Control But Not Overall Survival in Women with Breast Cancer and One to Three Positive Nodes Practice Update Editorial Team

Author: Tam Moses Conference: ASTRO Abstract 326

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update

Author: Recht A Reference: J Clin Oncol. 2016 Dec 20;34(36):44314442

NRG Oncology/RTOG 1014: 3 Year Efficacy Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal Partial Breast Re-Irradiation (PBrI) for In Breast Recurrence

Author: D. W. Arthur Conference: ASTRO LBA-10

Reviewer: Anusheel Munshi

09.45-09.55 (10mins)

Nipple-Sparing Mastectomy Shown to Be Safe - and Increasingly Preferred

Author: James Jakub, Conference: American Society of Breast Surgeon

Tina J. Hieken Abstract 0173 and ASCOPOST review

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study Author: Marissa C van Maaren Reference: The Lancet Oncology Volume 17, No. 8, p1158-1170, August 2016

Reviewer: Anupama Mane

09.55-10.10 (15mins)

Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study

Author: A. Mahajan Reference: Int J Radiat Oncol Biol Phys, October 1,

2016 Volume 96, Issue 2, Supplement,

Page S2



- N107C/CEC.3: A Phase III Trial of Post Operative Stereotactic Radiosurgery (SRS)
 Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
 Author: P. D. Brown
 Conference: ASTRO LBA 1
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial Author: Paul D. Brown Reference: JAMA. 2016 Jul 26;316(4):401-9
- Reviewer: Ashwini Budrukkar

10.10-10.15 (5mins)

Chairpersons Remarks

10.15-11.00 (45mins)

Chairpersons: Rajesh Vashistha, Vijay Haribhakti

Panel Discussion on Locoregional Therapies in Breast Cancer

Moderator: Sanjoy Chatterjee

Panelist: Anupama Mane, Shalaka Joshi, Archana Shetty, Anil Heroor,

Namita Pandey, Tabassum W., V Kannan, Vedant Kabra, Saniav Sharma, Nita Nair, Vikram Maiva, Manish Chandra

11.00-11.15 (15mins)

Tea / Coffee Break

11.15-13.15 Session 2: Translational Science

Chairpersons: Ramesh Nimmagadda, R K Deshpande

11.15-11.30 (15mins)

- Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

 Author: Cohen O Conference: 2016 SABCS S1-01
- The genomic landscape of male breast cancers

 Author: Salvatore Piscuoglio Reference: J Clin Oncol. 2016 Aug 15;22(16):4045-56
- Genomic Characterization of Primary Invasive Lobular Breast Cancer

 Author: Christine D Reference: J Clin Oncol. 2016 Jun 1;34(16):1872-81
- Reviewer: Amit Verma



Day 1 - Saturday, 21st January 2017

11.30-11.40 (10mins)

Prognostic and predictive value of circulating ESR1 mutations in metastatic breast cancer patients (mBC) progressing under aromatase inhibitor (AI) treatment Author: L Augusto Conference: 2016 ASCO Annual Meeting, Abstract 511

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer Author: Charlotte Fribbens Reference: J Clin Oncol. 2016 Sep 1:34(25):2961-8

Reviewer: Rejiv Rajendranath

11.40-11.55 (15mins)

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial Author: Prat Aparicio A Conference: 2016 SABCS S3-03

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Author: Fatima Cardoso Conference: AACR Abstract CT039 & N Engl J Med 2016: 375:717-729

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy **Author: Richard Buus** Reference: JNCI J Natl Cancer Inst (2016) 108(11):djw149

Reviewer: Manish Singhal

11.55-12.10 (15mins)

B.B. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin © and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Author: Han HS Conference: 2016 SABCS S2-05

DNA repair deficiency biomarkers and MammaPrint high1/(ultra) high 2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Author: Wolf DM Conference: 2016 SABCS S2-06



Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

Author: HS Rugo Reference: N. Engl. J. Med; 2016 Jul 7; 375(1)23-34

Reviewer: Adwaita Gore

12.10-12.25 (15mins)

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

Author: Fabrice Andre Reference: J Clin Oncol. 2016 Jun 20;34(18):2115-24

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial

Author: Sarat Chandarlapaty Reference: JAMA Oncol. 2016 Oct 1;2(10):1310-1315

Reviewer: T P Sahoo

12.25-12.30 (5mins)

Chairpersons Remarks

12.30-13.15 (45mins)

Chairpersons: Asha Kapadia, Madhuchanda Kar

Panel Discussion on Translational Science

Moderator: BKSmruti

Panelist: Rajiv Sarin, Shaheenah Dawood, Amit Verma, Vijay Agarwal, Vinod Raina,

Sudeep Gupta, AVS Suresh, Tanuja Shet, Seema Gulia, Amit Dutt, PP Bapsy

13.15-14.00 (45mins)

(1) Lunch Break

14.00-14.20 (20mins)

Chairpersons: Ramesh Bilimagga, K C Gopinath

Debate: AI (with ovarian suppression) is now the preferred adjuvant endocrine therapy in premenopausal patients with ER positive disease

Yes: Shaheenah Dawood No: Senthil Rajappa



Day 1 - Saturday, 21st January 2017

14.20-16.05 Session 3: HER2+ve Breast Cancer

Chairpersons: AK Malhotra, SH Advani

14.20-14.35 (15 mins)

A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-52 Author: Rimawi MF Conference: 2016 SABCS S3-06

Pathologic complete response rates after neoadjuvant trastuzumab emtansine + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE)

Author: Hurvitz SA Conference: 2016 ASCO Annual Meeting, Abstract 500

Association of Pathologic complete Response to Neoadjuvant therapy in HER+ve Breast Cancer with Long Term Outcomes: A Meta Analysis Reference: JAMA Oncol. 2016 Jun 1;2(6):751-60 Author: Kristine R. Broglio



14.35-14.50 (15 mins)

Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer Conference: 2016 SABCS S3-04 Author: Grazia Arpino

B'81 T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab Author: Hannah Dzimitrowicz Reference: Journal of Clinical Oncology 34, no. 29 (October 2016) 3511-3517

B'81 PHEREXA: A phase III study of trastuzumab + capecitabine +/- pertuzumab for patients who progressed during/after one line of trastuzumab-based therapy in the HER2 positive metastatic breast cancer setting

Author: Urruticoechea A Conference: 2016 ASCO Annual Meeting, LBA 503

Reviewer: Shaheenah Dawood



14.50-15.00 (10 mins)

- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer, The NEfERT-T Randomized Clinical Trial Author: Ahmad Awada Reference: JAMA Oncol. 2016 Dec 1:2(12):1557-1564
- learning Meratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo controlled, phase 3 trial Author: Arlene Chan Reference: Lancet Oncol. 2016 Mar; 17(3):367-77

8 Reviewer: Muzammil Shaikh

15.00-15.15(15mins)

Association of Polymorphisms in FCGR2A and FCGR3AWith Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer Analysis of the NSABP B31 Trial

Author: Patrick G. Gavin Reference: JAMA Oncol. 2016 Nov 3

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab A Secondary Analysis of the HER A Trial

Author: Sherene Loi Reference: JAMA Oncol. 2016 Aug 1;2(8):1040-7

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial

Author: Edith A. Perez Reference: J Natl Cancer Inst. 2016 Oct 28:109(2)

Reviewer: Jaya Ghosh

15.15-15.20 (5mins)

Chairpersons Remarks

15.20-16.05 (45mins)

Chairpersons: Tomcha Singh, C J Tamane

Panel Discussion on HER2+Ve Breast Cancer

Moderator: Senthil Rajappa

Panelist: Chetan Deshmukh, Shirish Alurkar, Bharat Bhosale, Kannan Kalaichelvi,

> Kaustav Talapatra, Santam Chakraborty, Shailesh Bondarde, Jaya Ghosh, Amit Agarwal, Avinash Deo, Manisha Singh



Day 1 - Saturday, 21st January 2017

16.05-16.20 (15mins)



Tea / Coffee Break

16.20-17.45 Session 4: Triple Negative Breast Cancer

Chairpersons: K. Pavithran, N. K. Warrier

16.20-16.30 (10mins)

MERIBEL, a phase 2, multicenter, single -arm trial to evaluate Eribulin therapy for aggressive taxane - resistant HER2-negative metastatic breast cancer (ESMO) Author: V Ortega Reference: Annals of Oncology (2016) 27 (6): 6899. 10.1093 /annonc/mdw365 (ESMO 2016)

Eribulin induces vascular remodelling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab Author: Ueda S Conference: 2016 SABCS P4-02-01

Reviewer: Sandeep Goyle

16.30-16.45 (15mins)

- ABC Joint Analysis: Optimal Chemotherapy Backbone for HER2-Negative EBC: TC vs TaxAC in HER2-Negative EBC (ABC Joint Analysis): Timeline, Accrual, Treatment Author: Joanne Lorraine Blum Conference: 2016 ASCO Annual Meeting, Abstract 1000
- Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer, A Randomized Clinical Trial Author: Theodoros Foukakis

Reference: JAMA. 2016;316(18):1888-1896

Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer Author: Peng Yuan Conference: 2016 ASCO Annual Meeting, Abstract 1068

Reviewer: AK Vaid



16.45-16.55 (10mins)

Capecitabine Monotherapy Extends Life and Benefits Patients Age 70 Years and Older with Metastatic Breast Cancer

Author: Stephen Johnston Conference: 2016 ESMO 240 P

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGIC Randomized Clinical Trial

Author: Chu MP Reference: JAMA Oncol. 2016 Oct 13

Reviewer: G S Bhattacharyya

16.55-17.00 (5mins)

Chairpersons Remarks

17.00-17.45 (45mins)

Chairpersons: J K Singh, K. C. Lakshmaiah

Panel Discussion on Triple Negative Breast Cancer

Moderator: Ashish Bakshi

Panelist: Anita Ramesh, J S Sekhon, Reetu Jain, T P Sahoo,

Bhavna Parikh, Devavrat Arya, Mehboob Basade,

Ranga Rao, SVSS Prasad

17.45-18.05 Session 5 : Rapid Review : Part 1

Chairpersons: Tanweer Shahid, Bharat Parikh

17.45-18.05 (20mins)

Reviewer: Shona Nag

1. Expert Critique: Node-Positive Breast Ca: Door Opens to SLN After Neoadjuvant Chemo - False-negative rates lower with advances in surgical techniques (ACOSOG, Alliance Z1071 trial, The SN FNAC Study, SENTINA trial)

Author: Mateusz Opyrchal Reference: Medpage Today ASCO Reading room

Q

Day 1 - Saturday, 21st January 2017

2. Axillary Lymph Node Dissection Can Largely Be Avoided in Breast Cancer (Z11 and Sound trial)

Author: Melissa Louise Conference: 18th Annual Lynn Sage Breast
Pilewskie Cancer Symposium Discussion

3. A model to predict axillary nodal pathologic complete response following neoadjuvant chemotherapy for breast cancer

Author: O Kantor Conference: 2016 ASCO Annual Meeting,
Abstract1047

4. Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

Author: D Hyman Conference: 2016 SABCS PD2-08

- 5. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study

 Author: Kala Visvanathan Reference: J Clin Oncol. 2016 Nov 21
- 6. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial Author: J Balmaña Conference: 2016 ESMO 2230
- 7. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: AMeta-analysis of Randomized Trials

Author: Clavarezza M Reference: Clin Cancer Res; 22(18); 4594-603

- 8. Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer the UK EPHOS-B trial (CRUK/08/002)

 Author: N. Bundred Conference: 2016 EBCC 6LBA
- 9. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Reference: Lancet Oncol. 2016 Dec 6. pii: \$1470 2045(16)30631-3



- 10. Original Investigation: RNA Sequencing to Predict Response to Neoadjuvant Anti HER2 Therapy. A Secondary Analysis of the NeoALTTO Randomized Clinical Trial Author: Debora Fumagalli Reference: JAMA Oncol. 2016 Sep 29
- 11. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III
 Randomized Trial
 Author: Amir Sonnenblick Reference: J Natl Cancer Inst. 2016 Apr 20:108(8)
- 12. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

 Author: Nolan Priedigkeit Reference: JAMA Oncol. 2016 Dec 7
- 13. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer

 Author: Nadine M. Tung Reference: npj Breast Cancer 2, Article number: 16002 (2016)
- 14. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC

 Author: Joel S. Parker Reference: J Clin Oncol 33, 2015 (suppl; abstr 1083)
- 15. Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple
 Negative Breast Cancer Outcomes

 Author: Ritu Aneja Conference: AACR Abstract B12
- 16. A phase II, open-label, multicentre, translational study for biomarkers of eribulin mesylate: evaluation of the utility of monitoring epithelial-to-mesenchymal transition (emt) markers on tumour cells in the malignant plural effusion of patients with metastatic breast cancer (expect-study)

 Author: Watanabe

 Conference: 2016 SABCS 0T1-01-01
- 17. Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy

 Author: Priyanka Sharma

 Conference: 2016 ASCO Annual Meeting
- Abstract 1015
- 18. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer

 Author: K Rhiem Conference: 2016 ASCO Annual Meeting,

Abstract 1090

Day 1 - Saturday, 21st January 2017

19. Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer

Author: Chiun-Sheng Huang

Conference: 2016 ASCO Annual Meeting,

Abstract 1003

20. Randomized, double blind trial to evaluate the safety and efficacy of metformin vs placebo plus neoadjuvant chemotherapy in locally advanced breast cancer Author: CArce-Salinas Conference: 2016 ASCO Annual Meeting.

Abstract 579

21. A phase II, multicentre, randomised trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Author: Park et al

Conference: 2016 SABCS OT1-01-12

- 22. PAINTER: Evaluation of eribulin tolerability and correlation between a set of Polymorphisms and neuropathy in patients with metastatic breast cancer Author: La Verde Conference: 2016 SABCS OT1-01-05
- 23. Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study Author: Nis P. Suppli Reference: JCO.November 14, 2016
- 24. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer.

Conference: JAMA Cardiology, 2016 Oct 12 Author: Husam Abdel-Qadir

25. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis

Author: Charles Guenancia Reference: J Clin Oncol. 2016 Sep 10;34(26):3157

65

26. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Author: D Zardavas

Reference: J. Clin. Oncol 2016 Oct 23



27. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: A population study

Author: Hart A. Goldhar Reference: JNCI J Natl cancer Inst (2016) 108(1)

- 28. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative ERBB2-positive breast cancer

 Author: C Dang Reference: JAMA Oncol. 2016 Jan; 2(1):29-36
- 29. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome

 Author: Pamela N. Munster Reference: JAMA Oncol. 2016 Aug 1;2(8):1089-90
- 30. Endocrine therapy for hormone receptor-positive metastatic breast cancer:
 American Society of Clinical Oncology guideline
 Author: Rugo HS Reference: J Oncol Pract. 2016 Jun; 12(6):583-7
- 31. Do all patients with advance HER2 positive breast cancer need upfront cemo when receiving trastuzumab? Randamized phase III trial SAKK 22/29

 Author: Pagani O Reference: Ann Oncol. 2016 Dec 19. pii: mdw622.

doi:10.1093/annonc/mdw622

19.30 (Onwards)

Banquet Dinner at Hooves



Day 2 - Sunday, 22nd January 2017

07.30-08.30 Meet The Experts

Experts: Vikram Maiya, Nita Nair, Anupama Mane, Bhawna Sirohi, Shona Nag, Prasad Dandekar

08.30-09.51 Session 6: Supportive Care

Chairpersons: Indumati Ambulkar, Ranga Rao

08.30-08.42 (12mins)

Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia

Author: Hope Rugo Conference: 2015 ASCO Annual Meeting, Abstract 9518

Scalp-Cooling Device Safe and Effective in Reducing Chemotherapy-Induced Alopecia in Women With Breast Cancer

Author: Julie Nangia Conference: 2016 SABCS S5-02

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Author: W Lu Conference: 2016 SABCS PD4-01

Reviewer: Jyoti Bajpai

08.42-08.52 (10mins)

Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (Al) associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202)

Author: Henry NL Conference: 2016 SABCS S5-06

Higher Rate of Severe Toxicities in Obese Patients Receiving dose-dense (dd)
Chemotherapy according to Unadjusted Body Surface Area- Results of the Prospectively
Randomized GAIN study

Author: J. Furlanetto Reference: Ann Oncol. 2016 Nov;27(11):2053-2059

Reviewer: Krishna Prasad



08.52-09.04 (12mins)

- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

 Author: Rudolph M. Navari Reference: NEJM N Engl J Med 2016; 375:134-142
- Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs)

 Author: J-J. Body

 Conference: 2016 ESMO 1463 P
- Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis

 Author: Omar Abdel-Rahman Reference: Expert Rev Anticancer Ther. 2016 Aug;

 16(8): 885-91



09.04-09.16 (12mins)

- Aromatase Inhibitors: Is Cancer Benefit Worth Cardiac Risk?

 Author: Anne H. Blaes Conference: 2016 SABCS S5-07
- Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study

Author: S Kamaraju Conference: 2016 SABCS PD4-07

- The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post menopausal women with early stage breast cancer

 Author: Husam Abdel-Oadir Reference: EJC. November 2016 Volume 68, Pages 11-21
- Reviewer: Hemant Malhotra

09.16-09.21 (5mins)

Chairpersons Remarks

09.21-09.51 (30mins)

Chairpersons: Jeremy Pautu, Shekhar Salkar

Panel Discussion on Supportive Care

Moderator: Bhawna Sirohi

Panelist: Dinesh Pendharkar, Shekhar Patil, Nirmal Raut, Ashish Kaushal,

Gaurav Gupta, Anubha Bharthuar, Manish Kumar, Amol Dongre,

Nikhil Ghadyalpatil, Arun Warrior, Kishore Kumar,



Day 2 - Sunday, 22nd January 2017

09.51-10.06 (15mins)



Tea / Coffee Break

10.06-12.58 Session 7: ER+Ve Breast Cancer

**

Chairpersons: Hemant Malhotra, Gurpreet Singh

10.06-10.22 (16mins)

Addition of ovarian function suppression to endocrine therapy in premenopausal women with early breast cancer: A meta-analysis

Author: Chlebowski R Conference: 2016 SABCS P2-09-06

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy Author: Bellet M Reference: J Clin Oncol. 2016 May 10;34(14):1584-93

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials

Author: Regan MM Reference: J Clin Oncol. 2016 Jul 1;34(19):2221-31

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Author: Karin Ribi Reference: J Clin Oncol. 2016 May 34, (14) 1601-1610



Reviewer: Nitesh Rohatgi

10.22-10.32 (10mins)

Can chemotherapy and endocrine therapy be given concurrently in ER positive MBC?



Reviewer: Amit Agarwal



10.32-10.48 (16mins)

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC)

Author: Finn RS Conference: 2016 ASCO Annual Meeting. Abstract 507 &

N Engl J Med 2016 Nov17; 375(20):1925-1936

- Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients

 Author: Hope rugo Conference: 2016 ESMO 225 PD
- Efficacy of Palbociclib Plus Fulvestrant in Patients With Metastatic Breast Cancer and ESR1 Mutations in Circulating Tumor DNA

 Author: Nicholas C Turner Conference: 2016 ASCO Annual Meeting, Abstract 512
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
 Author: Gabriel Hortobagyi Conference: 2016 ESMO LBA1 & N Engl J Med. 2016 Nov3
 ;375(18):1738-1748
- Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer Author: Hurvitz S Conference: 2016 SABCS S4-06

Reviewer: Shvam Aggarwal

10.48-11.04 (16 mins)

BELLE-3 Trial of Buparlisib Plus Endocrine Therapy Meets Primary Endpoint of Progression Free Survival in Breast Cancer Patients

Author: Di Leo A Conference: 2016 SABCS S4-07

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Author: Friedman LS Conference: 2016 SABCS S6-04

A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)

Author: M. Martin Reference: Ann Oncol. 2016 Nov 1



Day 2 - Sunday, 22nd January 2017

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo controlled, phase II randomised PEGGY study

Author: P. Vuylsteke Reference: Ann Oncol. 2016 Nov 1. pii: mdw562



Reviewer: Nita Nair

11.04-11.19 (15mins)

- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Author: John FR Robertson Reference: Lancet. 2017 Dec 17;388(10063):29973005
- Precog 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2 negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy Author: Kornblum N Conference: 2016 SABCS 51-02
- BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)

Author: M Royce Conference: 2016 ESMO 2220



Reviewer: T Raja

11.19-11.24 (5mins)



Chairpersons Remarks

11.24-11.54 (30mins) Key Note Address by Hope Rugo: Extended Adjuvant Endocrine Therapy in Breast Cancer: At Crossroads

Chairpersons: S D Banavali, Vijaykumar DK

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Author: Blok EJ Conference: 2016 SABCS 51-04



A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42

Author: Mamounas EP Conference: 2016 SABCS S1-05

First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Author: Tjan-Heijnen VC Conference: 2016 SABCS \$1-03

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial

Author: EJ Blok Conference: 2016 SABCS PD2-07

Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)

Author: Hongchao Pan Conference: 2016 ASCO Annual Meeting, Abstract 505

- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

 Author: Hurvitz S Reference: N Engl J Med. 2016 Jul 21;375(3):209-19
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

 Author: J R Buus Reference: J Natl Cancer Inst. 2016 Jul 10:108(11)
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up:
 Results From the International Breast Cancer Study Group Trials I to V

 Author: Colleoni M Reference: Ann Oncol. 2016 May: 27(5):806-12

11.54-12.14 (20mins)

Chairpersons: PP Bapsy, Shailesh Talati

Debate:

Fulvestrant is the appropriate 1st line option for low volume metatstatic Er+Ve disease - Chanchal Goswami

VS

Letrozole + Palbociclib is the appropriate 1st line option for low volume metatstatic Er+Ve disease - Chirag Desai

Day 2 - Sunday, 22nd January 2017

12.14-12.59 (45 mins)

Chairpersons: G S Chowdhary, Amish Dalal

Panel Discussion on ER+ve Breast Cancer

Moderator: Hope Rugo

Panelist: Somashekar S P. Chanchal Goswami, Vashishth Maniar,

Boman Dhabhar, B K Smruti, Chirag Desai, Sankar Srinivasan,

Poonam Patil, T Raja, Shyam Aggarwal, Ashish Singh, Nitesh Rohatgi,

12.59-13.19 Session 8: Rapid Review: Part 2

Chairpersons: N Sudhakar, Kajal Shah

12.59-13.19 (20 mins)

2 Reviewer: Dr. Sudeep Gupta

B381 Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study

> Author: Jagsi R Conference: 2016 SABCS S3-07

8,8 2. US Surgeons Snipe at UK's DCIS Trial, Who, in Turn, Cry Foul.LORIS TRIAL CONTROVERSY

Author: Melissa Pilewskie Reference: Medscape, Oct 16 Daniel Rea

B.SI 3. Expert Critiquie: Multicentric Breast Cancer: OK for Breast Conservation? Data

show the surgery is feasible, with good oncologic outcomes

Author: Laura M. Spring Reference: Medpagetoday review

B.SI 4. Noncoding somatic and inherited single-nucleotide variants converge to promote

ESR1 expression in breast cancer

Author: Swneke D Bailev Reference: Nature Genetics 48, 1260-1266(2016)

B.B. 5. Can surrogate pathological subtyping replace molecular subtyping? Outcome

results from the MINDACT trial

Author: F Cardoso Conference: 2016 SABCS PD7-01



6. Circulating Tumour Cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Author: J-Y. Pierga Reference: Annals of oncology, October 18, 2016

7. Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study

Author: S Delaloge Conference: 2016 ASCO Annual Meeting,

Abstract 1013

8. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial

Author: HM Earl Conference: 2016 ASCO Annual Meeting,

Abstract 1014

9. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Author: Dickler MN Reference: J Clin Oncol. 2016 Aug 1;34(22):2602-9

10. Effect of progesterone receptor on outcome of women with breast cancer

Author: SS Dawood Conference: 2016 ASCO Annual Meeting, Abstract 573

13.19-13.20 (1 min)



13.20 Onwards

Lunch and Departures



Partners

Prime Partners











Associate Partners















Be part of the practice changing deliberations Be there



FRI 19 - SUN 21 JAN, 2018

R. D. Choksi Auditorium, Tata Memorial Hospital, Mumbai



It is vast...but don't get lost...access virtual meetings on www.yearinreview.in Q

- India's 1st dedicated virtual meeting website
- 15 conference proceedings, already streaming
- More than 400 speakers presentation
- More than 50 panel discussions
- Exclusive platform to host your conference proceedings
- Proceedings

 Section on tumor board and virtual classroom

 and place by Brief Parks Charles Graphs Graph

 by Price Roads of Basics

 company of Bas







Registration Form

(Please fill the form in capital letters)						
Participants Details:							
Full Name:							
Mobile No:	Email Id:						
Institution:							
Department:	Specialization:						
Postal Address:							
City:	State:						
Payment Details:							
Amount:							
DD/Cheque No:							
Bank Name:							
Conference Registration Fee							
Faculty / Delegates	Rs. 1000/-						
Students	Rs. 500/-						

Kindly make the Demand Drafts or Cheque in favor of "NAG Foundation" & Courier it along with the registration form to the below address of conference secretariat. Students are requested to submit necessary proof from HOD For more information on registration please visit www.yearinreview.in or write to yir.breastcancer@gmail.com

Conference Secretariat:



Rekha Ghorpade

RIVER ROUTE Creative Group Pvt. Ltd.
Unit No. 2, Cama Industrial Premises Co-Op Society Ltd. Sunmil Compound,
Lower Parel (W), Mumbai - 400 013

Mobile: +91 8082764779 Tel: +91 22 24931357/58, Email: yir.breastcancer@gmail.com







Decoding the MILLAN Breast Cancer Conference

18th - 20th, August 2017, Pune

Innovation In Science And Care •



Dear Colleagues,

It is with pleasure that the Jehangir Breast Care Centre presents for the first time in India "Decoding the Milan Breast Cancer Conference" on the 18th-20th August 2017 in Pune. This conference will be held under the aegis of European Institute of Oncology and is supported by Women's Cancer Initiative - Tata Memorial Hospital.



The Milan Breast Cancer Conference has been developed more than 15 years ago to specifically provide the audience of breast cancer professionals and scientists with education and discussion on progress in the field. The Milan Breast Cancer Conference will be held on 22nd-23nd June, 2017 Milan Italy.

At the Indian Edition we will be inviting international experts from the Milan group, who will be presenting the most exciting areas of innovation related to breast cancer and will discuss several important issues discussed at the MBCC in Milan. For the Indian edition of the Conference in August, 2017 we have decided to maintain the theme of Innovation in Science and Care.

Looking forward to seeing you.

Regards

Conference Chairs



Dr. Roberto Orecchia

Professor of Radiotherapy, University of Milan Director of the Radiology Science Department, IEO (European Institute of Oncology). Scientific Director, IEO

Dr. Shona Nag

Head Dept of Medical Oncology Jehangir Hospital, Pune

Dr. Sudeep Gupta

Deputy Director, ACTREC, Professor of Medical Oncology, Tata Memorial Centre

Dr. Anupama Mane

Consultant Breast Surgeon Jehangir Breast Care Center Jehangir Hospital, Pune

International Speakers



Roberto Orecchia

Scientific Director, Graduated in medicine with three specializations: radiation therapy, medical oncology and diagnostics imaging.

Professor of radiation oncology at the University of Milan and Director of the Division of radiation of the European Institute of Oncology, Milan (IEO). Former President of the Italian Association of Oncological radiotherapy AIRO and Director of the school of specialization in radiotherapy, currently he covers the roles of Director of Medical imaging andradiation sciences of the IEO, scientific Director of CNAO and scientific co-director of IEO. He is the author of about 300 publications in prestigious scientific national and international journals.



Giuseppe Viale

The director of the Division of Pathology and Laboratory Medicine at the European Institute of Oncology in Milan.

Professor Viale's scientific interests include the validation of predictive and prognostic markers in breast cancer, the abnormal expression of oncogenes and tumor-suppressor genes in human malignancies, the derangements in cell-cycle control and apoptotic pathways, and the role of angiogenesis in tumor progression.

He is the chairman of the Central Pathology Office of the International Breast Cancer Study Group (IBCSG), lead pathologist of the Breast International Group (BIG), and co-chair of the Translational Research Committee of the BIG2-98 trial (Trans-TAX).

He is also an active member of many international societies, organizations, and committees, including the American Joint Committee on Cancer (AJCC) working group for the TNM classification of breast cancer, the Pathology Sub-Study Group of the Intergroup Exemestane Study (PathIES), the Executive and Steering Committees of the ALTTO and APHINITY trials (running the Central Pathology Laboratory), the Formalin-Fixed, Paraffin-Embedded Tissue (FFPE) Working Group of the Breast International Group (BIG) and National Cancer Institute (NCI)—sponsored breast cancer Cooperative Groups, the Early Breast Cancer Trialists' Collaborative Group Steering Committee, and the Translational Research Committee of the HERA trial. He is also a founding member of the International Sentinel Node Society. He has authored 478 articles in peer-reviewed international journals and 36 chapters in books.



Professor Mario-Rietjens

Director of the Division of Plastic and Reconstructive Surgery of the European Institute of Oncology in Milan since 2011. He has held various academic positions in the Division of Plastic and Reconstructive Surgery at the European Institute of Oncology in Milan from 1994.

He has done extensive work in the field of Surgical Oncology and Reconstructive Plastic Surgery (breast, skin, gynecological, abdominal and thoracic spine). His major clinical research work has been in field of reconstructive plastic surgery and more specifically on the issues of diagnostic strength and durability of silicone gel breast implants, techniques of lipofilling (autologous fat transplantation) to repair breast after mastectomy or quadrantectomy. He has been a leader in development of new surgical techniques in "Oncoplastic Surgery" and new techniques of gynecological reconstruction following an extensive demolition for cancer

He organizes annual teaching course at the IEO: Breast Cancer and Reconstructive Surgery since 2004. He also organises annual course of surgical techniques on cadavers at the Miami Anatomical Research Center. He is the author of 72 articles in prestigious journals, 12 book chapters and editor of 4 books on surgery.



Professor Virgilio Sacchini

Breast surgeon at Memorial Sloan Kettering Cancer Center in New York and Full Professor at Cornell University, recently has joined University of Milan to hold the office of Professor of General Surgery. He is also in-charge of clinical activity and research, as part of his academic position, at the European Institute of Oncology in Milan, as Director of the Breast Care program.

His return at the European Institute of Oncology, where he started sixteen years ago to work in the biggest center of US Oncology, enriched with clinical experience and the already prestigious American research Division of Senology of the European Institute of Oncology . In particular it develops the genetics and genomics of breast cancer , to extend and refine the applications of precision medicine , strategic pillar of the IEO, together with a multidisciplinary approach and the culture of the person. Professor Sacchini, with his expertise and his international vision, is also contributing to develop the IEO Women's Cancer Center: the innovative center dedicated to all the women's oncological problems.



Giuseppe Curigliano

He is the Co-Chair of the Division of Medical Oncology and Director of the New Drug Unit at European Institute of Oncology, in Milan.

He is a clinician and researcher specialising in breast cancer.

He has led several translational research protocols on breast and urogenital cancer. He has been part of an important phase I - II drug development units, contributing to successful development of several targeted agents and cytotoxics. Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breastcancer at European Institute of Oncology.

He is a founding member of/and scientific coordinator for the International Cardio-OncologySociety (ICOS). He is a member of the Scientific Advisory Committee of the International BreastCancer Study Group. He is a member of the Scientific Advisory Committee of the Breast International Group (BIG). He is an active member of the Immuno-Task force of the BIG and active member of the BIG-NABCG Immuno Task Force. He has several publications to his credit in many reputed journals.











Registration Form

(Please fill the form in capital letters)		
Participants Details:		
Full Name:		
Mobile No: ————	Email Id: —	
Institution:		
		on: —————
Postal Address: —		
Payment Details:		
Amount:		DD/Cheque No:
Bank Name:		

	Registration till 31 st March 2017	Registration after 31st March 2017 till 30th June 2017	Registration after 30 th June 2017
Delegates			
Radiology Workshop	2000	2500	3000
Pathology Workshop	2000	2500	3000
Workshop + Conference	6000	7000	8000
Conference	5000	6000	7000
Students			
Radiology Workshop	500	1000	1500
Pathology Workshop	500	1000	1500
Workshop + Conference	1500	2000	2500

For Registration Please Visit www.nagfoundation.org/dmbcc/registration.html

Kindly make the Demand Drafts or Cheque in favor of "NAG Foundation" & Courier it along with the registration form to the below address of conference secretariat. Students are requested to submit necessary proof from HOD For more information on registration.

Conference Secretariat:



Rekha Ghorpade

RIVER ROUTE Creative Group Pvt. Ltd.

Unit No. 2, Cama Industrial Premises Co-Op Society Ltd. Sunmil Compound, Lower Parel (W), Mumbai - 400 013

Mobile: +91 8082764779 Tel: +91 22 24931357/58, Email: yir.breastcancer@gmail.com